David Kerr

CBE FMedSci FRCP

Professor of Cancer Medicine

Consultant Physician

Genetics and Genomics

In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.

Key publications

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article

Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557

Recent publications

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study.
Journal article

Lee LYW. et al, (2020), Lancet Oncol
The burgeoning role of global health diplomacy to alleviate suffering of cancer patients in low- and middle-income countries.
Journal article

Adomako M. et al, (2020), Int Health, 12, 231 - 233
The Oncology Data Network (ODN): Methodology, Challenges and Achievements.
Journal article

Woolmore A. et al, (2020), Oncologist
Oncopolicy and global health diplomacy in times of rising populism.
Journal article

Adomako M. et al, (2020), J Public Health Policy
Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019).
Journal article

Ren L. et al, (2020), Eur J Surg Oncol

More publications